肺癌D-二聚体定量与抗凝血酶Ⅲ活性测定的意义  

Significance of measurement of D-dimer concentration and antithrombin-Ⅲ in lung cancer

作　　者：秦海明[1] 陈渝宁[2] 万楠[2] 方秀菊[2] 

机构地区：[1]沈阳军区总医院病理科,沈阳110016 [2]沈阳军区总医院检验科,沈阳110016

出　　处：《中国肿瘤临床与康复》2009年第6期506-507,共2页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的对119例肺癌患者D二聚体(D-dimer)和抗凝血酶Ⅲ(antithrombinⅢ,AT-Ⅲ)活性进行检测,以探讨上述指标与肺癌的关系及意义。方法肺癌患者119例,对照组30例。D二聚体定量(D-dimer)和抗凝血酶Ⅲ活性测定用STAGOSTA-Compact全自动凝血仪检测。结果肺癌患者D-dimer[(2.26±1.24)μg/ml]明显高于对照组[(0.31±0.25)μg/ml](P<0.01)。肺癌患者抗凝血酶Ⅲ活性[(73.03±24.66)%]低于对照组[(98.11±16.31)%];肺癌转移组(45例)D-dimer明显高于肺癌局限组(74例)[(2.96±1.51)μg/ml对(1.32±1.03)μg/ml,P<0.01]。结论肺癌患者均有不同程度继发纤溶亢进及抗凝活性减低。凝血及纤溶的异常在肺部肿瘤的发生和发展中起重要的作用。D-dimer测定对肺癌的转移及预后有重要的价值。Objective To investigate the significance of D-dimer and antithrombin-Ⅲ in patients with lung cancer. Methods The study comprised 119 lung cancer patients and 30 healthy persons. D-dimer and antithrombin Ⅲ were measured with Liatest method in SAGO STA-Compact Automatic analyzer. Results D-dimer concentrations in lung cancer patients were significantly higher than those in the controls（2. 26± 1.24 vs 0. 31 ± 0. 25 μg/ml, P 〈 0. 01 ）. Antithrombin-Ⅲ concentrations in lung cancer patients were significantly lower（73. 03 ±24. 66% vs 98. 11 ± 16. 31% ,P 〈0. 01 ）. The lung cancer patient group was classified into 2 subgroups according to with （ n = 45 ） or without （ n = 74） distant metastasis. D-dimer concentration was significantly higher in the former group than in the latter group（2. 96 ± 1.51 vs 1.32 ± 1. 03μg/ml, P 〈 0. 01 ）. Conclusion D-dimer concentrations and antithrornbin-Ⅲ were abnormal in lung cancer patients. This study indicates that there is increased D-dimer and decreased antithrombin-Ⅲ activity in patients with lung cancer. Abnormal blood coagulation and fibrinolysis play important roles in the occurrence and development of the disease.

关 键 词：肺肿瘤 D-二聚体 抗凝血酶Ⅲ 

分 类 号：R734.2[医药卫生—肿瘤] R730.43[医药卫生—临床医学]